Aumolertinib after surgery for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had surgery to completely remove your lung cancer (not just a small wedge).
- Your cancer is non-small cell lung cancer, but not the squamous type.
- Your cancer has an EGFR mutation (exon 19 deletion or exon 21 L858R).
- You are well enough to be active (performance status 0 or 1).
- You start the study treatment within 10 weeks after surgery and your wounds are healed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.